Evidence-based guidelines in acromegaly: implications on the clinic

References

• Katznelson L, Laws ER Jr., Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–3951.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141–3148.
   PubMed Web of Science ®Google Scholar
• Vieira Neto L, Abucham J, Araujo LA, et al. [Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil]. Arq Bras Endocrinol Metabol. 2011;55:91–105.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Atkinson JL, Cook DM, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract. 2011;17(Suppl 4):1–44.
   PubMed Web of Science ®Google Scholar
• Kastelan D, Dusek T, Vizner B, et al. [Croatian Society of Endocrinology guidelines for the diagnosis and treatment of acromegaly]. Lijec Vjesn. 2012;134:65–68.
   PubMedGoogle Scholar
• Cordido F, Garcia Arnes JA, Marazuela Aspiroz M, et al. grupo de Neuroendocrinologia de la Sociedad Espanola de Endocrinologia y N. [Practical guidelines for diagnosis and treatment of acromegaly. Grupo de Neuroendocrinologia de la Sociedad Espanola de Endocrinologia y Nutricion]. Endocrinol Nutr. 2013;60:457 e451–e457.
   Google Scholar
• Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16:294–302.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10:243–248.
   PubMed Web of Science ®Google Scholar
• Giustina A, Ambrosio MR, Beck Peccoz P, et al. Use of pegvisomant in acromegaly. An Italian society of endocrinology guideline. J Endocrinol Invest. 2014;37:1017–1030.
   PubMed Web of Science ®Google Scholar
• Woolf SH, Grol R, Hutchinson A, et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527–530.
   PubMed Web of Science ®Google Scholar
• Montori VM, Guyatt GH. What is evidence-based medicine? Endocrinol Metab Clin North Am. 2002;31:521–526.
   PubMed Web of Science ®Google Scholar
• Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice. ACP J Club. 2002;136:A11–A14.
   PubMedGoogle Scholar
• Evidence-Based Medicine Working G. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268:2420–2425.
   PubMed Web of Science ®Google Scholar
• Swiglo BA, Murad MH, Schunemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666–673.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
   PubMed Web of Science ®Google Scholar
• Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
   PubMed Web of Science ®Google Scholar
• Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA. 2009;301:868–869.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995–2010.
   PubMed Web of Science ®Google Scholar
• Bolanowski M, Ruchala M, Zgliczynski W, et al. Acromegaly – a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports. Endokrynol Pol. 2014;65:326–331.
   PubMed Web of Science ®Google Scholar
• Verrua E, Ferrante E, Filopanti M, et al. Reevaluation of acromegalic patients in long-term remission according to newly proposed consensus criteria for control of disease. Int J Endocrinol. 2014;2014:581594.
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Svartberg J, Schreiner T, et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin Endocrinol (Oxf). 2011;74:736–743.
   PubMed Web of Science ®Google Scholar
• Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. 2013;8:e61523.
   PubMed Web of Science ®Google Scholar
• Fougner SL, Bollerslev J, Svartberg J, et al. Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur J Endocrinol. 2014;171:229–235.
   PubMed Web of Science ®Google Scholar
• Nunes VS, Correa JM, Puga ME, et al. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary. 2015;18:500–508.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Pivonello R, et al. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2015 Oct 30. [Epub ahead of print].
   Google Scholar
• Fougner SL, Casar-Borota O, Heck A, et al. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf). 2012;76:96–102.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Wildemberg LE, et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012;19:L25–L29.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Wildemberg LE, Neto LV, et al. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol. 2013;169:217–223.
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98:E66–E71.
   PubMed Web of Science ®Google Scholar
• Gadelha MR. A paradigm shift in the medical treatment of acromegaly: from a ‘trial and error’ to a personalized therapeutic decision-making process. Clin Endocrinol (Oxf). 2015;83:1–2.
   PubMed Web of Science ®Google Scholar